Jean-Paul Prieels

20Med Therapeutics is a biomedical company developing innovative solutions for efficient intracellular delivery of RNA and DNA based vacccines and therapeutics. 20Meds proprietary highly innovative nanoparticles are designed with several smart functions that make them efficient in protecting fragile payload, transport, cellular uptake, and release of active Oligonucleotide based payloads into the cytoplasm of target cells. 20Meds nanoparticles are flexible in functionalization and their unique properties make them applicable in a broad field of medical therapeutics.

Quantoom Biosciences is reinventing mRNA production by developing an RNA Platform (Nfinity™) that encompasses DNA (Nplify™) and RNA (Ntensify™) manufacturing and formulation (Ncapsulate™), along with critical reagent supply, from sequence to large-scale production. We are a team of scientists, engineers, and clinicians committed to solving some of the biggest DNA and RNA production challenges facing vaccines and therapeutics, by delivering greater access and autonomy to mRNA technology. Our facilities are strategically located in Belgium and France, in the heart of Europe, benefiting from an exceptional biotech ecosystem. Quantoom Biosciences is part of Univercells, a global life sciences Group with the mission of making biologics accessible to all.

Cell Signaling Technology for Organ Repair and Regeneration We care for liver Our advanced therapy aims to restore liver function thanks to immunomodulatory and regenerative properties of Hepastem

Our mission is to help the life sciences field to develop and deploy health care products and services faster and better by developing innovative data-driven healthcare strategies. Our vision is to become a top-of-mind solution provider at an international level in this field. The health care industry is subject to wrong or inefficient diagnosis and therapeutic strategies. Difficulty to come with new efficient therapeutics and medical technologies have huge societal costs. This involves hospitals, laboratories, pharma/biotech, medtech, diagnostics, cell therapy, CROs, ... Strong trends consisting in hight pressure on budgets from health payers and patient empowerment also trigger a need for more tailored health care. The field is also under heavy data deluge (real-life, genomics, clinical, biology, demographics, … ) and adequate solutions need to be adopted to make the most out of these. Our approach is to use Data Science (Machine Learning, Statistics, Artificial Intelligence, Cloud Computing, Data Management, ...) to build new decision-support tools from public / private data to tackle these inefficiencies. We use this innovative approach on a rather traditional consulting model. Typical applications: - Clinical development - R&D - Diagnostics, prognostics, theranostics - Production and manufacturing excellence - Health policy-making - Patient care optimization A few numbers: - 2-digits growth every year since its inception. - Involved in ~30 scientific communications - More than half our turnover is made out of Belgium, a part of which out of EU. - Our machine learning library LiblineaR is downloaded worldwide >2000 times/month. - Our rheumatology platform rheumakit.com has >40.000 users/year.

Okairos is a clinical stage biopharmaceutical company spun off in 2007 from IRBM, a Merck, Inc. subsidiary located in Rome-Italy. Okairos develops genetic vaccines for major infectious diseases, including malaria, hepatitis C (HCV) and universal influenza, using a novel proprietary technology. The company’s laboratories are located in Rome and Naples, Italy, with corporate headquarters in Basel, Switzerland. Okairos’ technology platform is centered on the development of new, potent, replication-incompetent Adenovirus vectors, derived from strains isolated from chimpanzees and used to encode and deliver prophylactic and therapeutic antigens. These vectors have several major advantages over existing Adenoviral vectors: they are not neutralized by human sera, and they hold promise for generating effective T cell responses, where existing vectors have failed. Okairos’ Adenovirus vector platform is being used to generate a pipeline of T cell vaccines against a range of infectious diseases, for which there is currently no effective vaccine, as well as for cancer. Okairos intends to bring its core vaccine candidates through to the completion of Phase II proof-of-concept trials, and will seek partnerships to support Phase III trials and market its vaccines worldwide. Selected vaccine candidates outside of Okairos' core areas may be out-licensed at an early stage of development.

CuraVac is a clinical-stage biotech developing a new class of targeted therapeutic vaccines / immunotherapies for autoimmune diseases. Our first therapeutic vaccine is for myasthenia gravis (MG). Preclinical work is ongoing for other autoimmune diseases including MS and GBS. Future studies will focus on Graves' diease, Hashimoto's disease, Type 1 Diabetes, ...

20Med Therapeutics is a biomedical company developing innovative solutions for efficient intracellular delivery of RNA and DNA based vacccines and therapeutics. 20Meds proprietary highly innovative nanoparticles are designed with several smart functions that make them efficient in protecting fragile payload, transport, cellular uptake, and release of active Oligonucleotide based payloads into the cytoplasm of target cells. 20Meds nanoparticles are flexible in functionalization and their unique properties make them applicable in a broad field of medical therapeutics.

Quantoom Biosciences is reinventing mRNA production by developing an RNA Platform (Nfinity™) that encompasses DNA (Nplify™) and RNA (Ntensify™) manufacturing and formulation (Ncapsulate™), along with critical reagent supply, from sequence to large-scale production. We are a team of scientists, engineers, and clinicians committed to solving some of the biggest DNA and RNA production challenges facing vaccines and therapeutics, by delivering greater access and autonomy to mRNA technology. Our facilities are strategically located in Belgium and France, in the heart of Europe, benefiting from an exceptional biotech ecosystem. Quantoom Biosciences is part of Univercells, a global life sciences Group with the mission of making biologics accessible to all.

Cell Signaling Technology for Organ Repair and Regeneration We care for liver Our advanced therapy aims to restore liver function thanks to immunomodulatory and regenerative properties of Hepastem